Omnicare — Investor Day (September 2012)
60 slides from Omnicare's investor day presentation, Sep 18, 2012
Slide 1: Omnicare Specialty Summit September 18, 2012
Omnicare Specialty Summit September 18, 2012
Slide 2: Forward-Looking Statement
Forward-Looking Statement Certain of the statements made today and listed within the following presentation slides are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward- looking statements include, but are not limited to, all stateme
Slide 3: Agenda
Agenda • Welcome • Introductions and Overview • Specialty Care Group - Integrated Services • Specialty Market Dynamics • Brand Support Services • Closing Remarks • Tour 3
Slide 4: Introduction
Introduction John L. Workman Chief Executive Officer 4
Slide 5: Recent Changes
Recent Changes • John L. Workman, Chief Executive Officer • Nitin Sahney, President and Chief Operating Officer • Rocky Kraft, Chief Financial Officer 5
Slide 6: Pharmaceutical Market Dynamics: Continued Rise of Generics, Specialty Drugs
Pharmaceutical Market Dynamics Continued Rise of Generics, Specialty Drugs 63.4% 86.8% 50% 60% 70% 80% 90% 100% 2006 2015E Generic Drug Market Share 44.6 61.7 35 40 45 50 55 60 65 2006 2015E Specialty Drug Utilization – Total Prescriptions 6 1. Source: IMS – Total US Pharma Prescriptions Omnicare we
Slide 7: Overview
Overview Nitin Sahney Chief Operating Officer 7
Slide 8: Omnicare's Primary Businesses
Omnicare’s Primary Businesses Long-Term Care Group Specialty Care Group Business Overview Institutional pharmacy Specialty pharmaceutical services and end-of-life care management Customers Skilled nursing, assisted living and other chronic care institutions Patients, providers, care-givers, nurses,
Slide 9: Omnicare's Primary Businesses
Omnicare’s Primary Businesses $2,499.1M $623.4M $6.6M 2Q12 Year-to-Date Revenue Long Term Care Specialty Care Group Other 57.4M 3.5M 2Q12 Year-to-Date Prescription Count Long Term Care Specialty Care Group 9
Slide 10: Specialty Care Group Strategic Significance
Specialty Care Group Strategic Significance • Increase utilization of specialty products reshaping patient care • Extension of pharmaceutical services core competency • Diversification benefits provide for greater stability • Opportunity to better leverage both assets collectively 10
Slide 11: Omnicare's Five Operating Platforms
End of Life Care Brand Support Services Supply Chain Solutions Patient Support Services Specialty Pharmacy Specialty Care Group Omnicare’s Five Operating Platforms 11 Manufacturer Fee for Service Model Manufacturer owns the product Third Party Payers Buy/Sell Model Hospices Per Diem Model SCG owns t
Slide 12: SCG Revenue Characteristics
SCG Revenue Characteristics YTD 6/30/12 12 Payor Mix Revenue by Service Medicare Part D 54% Hospice 17% Commercial Insurance 10% Drug Manufacturers / Clients 12% Private Pay 3% Medicaid 1% Medicare Part B 1% Mail Order 1% Intercompany 1% Specialty Rx Dispensing 72% Hospice Dispensing 17% Brand Suppo
Slide 13: SCG Management Team Structure
SCG Management Team Structure Nitin Sahney President & Chief Operating Officer David Hileman SVP, SCG Operations Denise Von Dohren VP, Access Solutions John Doster VP, Brand Support Services Tom Stieritz SVP & General Manager, excelleRx Dennis Wilson SVP & General Manager, Advanced Care Scripts Dan
Slide 14: SCG Integrated Services
SCG Integrated Services David Hileman SVP, Omnicare Specialty Care Group Operations 14
Slide 15: Specialty Care Group
Specialty Care Group 15 Founded: 1981 Omnicare strategically acquired four companies with extensive experience to leverage synergistic services for manufacturers, providers, payers and patient communities. Founded: 1993 Acquired by Omnicare: 1997 Founded: 1985 Acquired by Omnicare: 2005 Founded: 199
Slide 16: Specialty Care Group Footprint
MS AL WI WV GA TN MI OH MN IN NC SC IL MD DE LA AR FL ME NJ RI VT NH MA CT IA PA VA NY MO KY Specialty Care Group Footprint Company Location HQ Pharmacy Call Center 3PL ACS Orlando, FL X X X excelleRx Philadelphia, PA X X excelleRx Sharon Hill, PA X excelleRx Memphis, TN X X PBM Plus Milford, OH X X
Slide 17: Market Challenges
Market Challenges • Payer – Utilization management controls • Prior Authorizations • Step Therapy • Governmental – Implementation of Affordable Care Act • Patient Assistance Programs become more complex • Increase in “under-insured” patient populations • Product – Cold chain focused on small patient
Slide 18: Impact Along the Product Path
Impact Along the Product Path 18 Providers Payers Distribution Patients Omnicare’s Specialty Care Group provides an integrated end-to-end solution for manufacturers
Slide 19: Integration Goals
Integration Goals Leverage Customized Distribution Capabilities • Direct to physician and patient • Institutional pharmacy expertise 19 1 2 3 Simplify Provider’s Involvement • Reduce barriers to prescribing • Overcome burdensome processes Engage the Patient • Web-tools • Social Media • Targeted Pati
Slide 20: Operations Building Success
Operations Building Success 20 • HUB Program Services • Reimbursement Solutions • Patient Assistance Management • Web Tools • SP Networks • Co-Pay Assistance • Compliance & Adherence • Clinical Management Product Fulfillment Brand Support Specialty Pharmacy
Slide 21: Integrated Service Example: Manufacturer Direct to Patient Programs
Integrated Service Example Manufacturer Direct to Patient Programs • Challenge – Product/Market characteristics have or will impact product sales • Lack of payer coverage • Distribution channel challenges • Increased brand competition • Patent expiration • Objectives – Enable patients to purchase pr
Slide 22: Integrated Service Example: Typical Supply Chain
Integrated Service Example Typical Supply Chain 22 Manufacturer Produces Product Product Purchased by Wholesaler Product Acquired by Pharmacy Patient Fills Prescription Using Manufacturer Produces Product Patient Fills Prescription Manufacturers can benefit from greater efficiency, consistency; Pati
Slide 23: A Market in Transition
A Market in Transition 23 As millions of patients gain insurance “coverage” Omnicare’s SCG believes it is well-positioned to adapt to the changing needs of our manufacturer clients The Transition Has Begun Reimbursement Support & Patient Access Centers will evolve - - - - - -2012- - - - - -2013 2011
Slide 24: SCG Differentiators
Sup p ly Chai n Manufacturer distribution direct to patient Manufacturer direct to physician for oncology products Specialty product management within the LTC channel Specialt y Pharmac y Single source product distribution partner Patient reimbursement services (co-pay and foundation programs) Brand
Slide 25: Target Customers & Characteristics
Target Customers & Characteristics Fee for Service Brand Support Patient Assistance 3rd Party Logistics Specialty Dispensing New Networks Foundation Programs Physician Sales Large Biotech/ Pharma Small/Orphan Biotech Biotech Access Networks PAP Programs Physician Offices • Complex Organization • Fra
Slide 26: Typical Deal Characteristics
Typical Deal Characteristics Fee for Service Specialty Dispensing Service Type Brand Support Patient Assistance 3rd Party Logistics New Specialty Pharmacy Provider (SPP) PAP – Foundation Physician Sales Sales Cycle 6 – 9 month 2 – 3 months 3 – 6 months 10 – 15 days Contract Tenure 3 years N/A 1 year
Slide 27: Typical Sales Process
Typical Sales Process Steps: Activities Process Owner Sales Activity Lead Sales Activity Support 1. Lead Generation • Client mapping • Research • Meeting • Pro-active selling Sales Team Sales Team Executive Team & Operations 2. Solution • Scope Q&A • Solution approach • Pricing • Program timetable •
Slide 28: Specialty Market
Specialty Market Denise Von Dohren Vice President, Access Solutions, SCG 28
Slide 29: Specialty Market Dynamics
Specialty Market Dynamics Specialty Products Payor Pressures Product Price Increases Biosimilars Co-Pay Challenges Regulatory (Affordable Care Act) Supply Chain Issues 29 Bio/Pharma pressured to go beyond traditional marketing and channel management
Slide 30: Specialty Market Dynamics
Specialty Market Dynamics • Robust pipeline – More than 900 specialty products in the pipeline (1) – Many therapy categories, oncology representing nearly half of the pipeline • Routes of administration (ROAs) – Benefits patients by improving access to specialty products – Does not address adherence
Slide 31: Specialty Market Dynamics
Specialty Market Dynamics • Rapidly growing market 31 Biotechnology Drugs, 9.0% Conventional Drugs, 72.0% Other, 19.0% 2000 Biotechnology Drugs, 23.0% Conventional Drugs, 55.0% Other, 22.0% 2014 est. Pharmaceutical Market Share(1) by Drug Type Specialty growing 4x faster than the traditional drug ma
Slide 32: Specialty Market Dynamics: Small is the New Big
Specialty Market Dynamics “Small is the New Big” • Orphan Drugs – Targeting rare conditions – 7 years exclusivity – Clinical trial awards of $200 to $400K per year – Lower risk associated with discovery – Smaller infrastructure to support Orphan drugs target 6,000-8,000 conditions that affect popula
Slide 33: Specialty Market Dynamics: Small is the New Big
Specialty Market Dynamics “Small is the New Big” 5 6 7 9 12 0 2 4 6 8 10 12 14 2007 2008 2009 2010 2011 Increasing Molecular Entity Launches with Orphan Status(1) More than 400 medicines in later stages of the development pipeline to treat or prevent rare diseases(2) 33 1. Source: IMS Institute for
Slide 34: Specialty Market Dynamics: Challenges Facing the Industry
1 Pharma Exec Survey, Booz & Co. and National Analysts Worldwide Survey, 2011 Specialty Market Dynamics What are the challenges facing the industry?(1) 76% Growing healthcare system price and budget pressures 70% Growing need to demonstrate cost effectiveness/outcomes 69% More restrictive market acc
Slide 35: Opportunity to Deliver Value Across Stakeholders
Opportunity to Deliver Value Across Stakeholders The Physicians Smooth Initiation of therapy Build brand loyalty Reduce staff time The Manufacturer Increase market share Deliver brand promise Competitive differentiation The Patient Remove barriers to access Increased speed to therapy Focus on health
Slide 36: Competition & Differentiators
Third Party Logistics (3PL) Brand Support Consigned Pharmacy Specialty Pharmacy Medication Therapy Management Competition & Differentiators Integration of Manufacturer Focused Services • Manufacturer focused • Enhanced speed to therapy • Flexible solutions adaptable to specific brand needs • Efficie
Slide 37: SCG Access Solutions
Nurse Support/Training Customized Distribution Patient Access Processing & Distribution Copay Programs Trial/”Quick Start” Program Specialty Pharmacy Social Media and Web tools Access to Providers & Patients SCG Access Solutions 37
Slide 38: Aligned to Market
Aligned to Market Growing Trend: Channel strategy + Brand support 38 Omnicare SCG believes it is well-positioned too capitalize on movement from HUB to Centralized Service Providers HUB Concierge/Call Ctr Reimbursement/Coverage Support Benefit Investigation Specialty Pharmacy Central Service Provide
Slide 39: Summary
Summary • Rapidly changing market dynamics • SCG integrated platforms enable customization to drive differentiation • Innovative programs to improve potential for commercial success 39
Slide 40: Brand Support Services
Brand Support Services John Doster Vice President, Brand Support Services, SCG 40
Slide 41: Brand Support Market
Brand Support Market 50 100 150 200 250 300 2009 2010 2011 2012e 2013e 2014e Reimbursement Hub Market(1) Patient Assistance Market(1) (Indigent Patient) Markets 2008 2009 2010 2011 2012 (est.) 2013 (est.) 2014 (est.) Patient Assistance Programs1 9% 7% 7% 2% (7%) (10%) (10%) Reimbursement Hub Program
Slide 42: Market Conditions
Market Conditions • Shifting corporate strategy and spend toward specialty products • Cost cutting within non-specialty product programs • Vendor consolidation – Cost considerations driving companies to consolidate patient support vendors • Competitor consolidation – Requires challenging integration
Slide 43: The Need for an External Partner
The Need for an External Partner • Economies of scale – Phone systems and patient management systems are expensive to build and maintain – Vendor can more effectively spread costs across customer base – Vendor gains insight and knowledge across programs that can be leveraged by individual company •
Slide 44: Third Party Logistics Market Basket: Centralized HUB Program
Third Party Logistics Market Basket 44 Centralized HUB Program • Patient Intake • General Program Services - Reimbursement Case Management - Co-pay Assistance - SP Triage - Patient Adherence Outreach - Indigent Patient Program Patient or Provider Accesses Program Direct to Physician Distribution Dir
Slide 45: Access Programs – Value Proposition
Access Programs – Value Proposition The Physicians Reduce staff time Increase office productivity Improved patient satisfaction Improve outcomes The Manufacturer Retain/increase business Insights into practice and SPs through data consolidation The Patient Enhanced care Faster approval/therapy Enhan
Slide 46: Key Competitors
Key Competitors Company Ownership Lash Group (Theracom) AmerisourceBergen HealthBridge/UBC/Proherent Express Scripts/Medco Access Med / McKesson Specialty McKesson Covance Market Access Covance inVentiv Patient Access Solutions inVentiv Health 46
Slide 47: Case Study
Case Study • Segment with highest percentage of specialty drug spend(1) • Competitive market with 4 entrenched products • Multiple indications for competition • One additional product approved in 2010 Marketplace Dynamics • New entrant in space with 2 dominant brands from “big” pharma/bio • Less tha
Slide 48: Brand Support Services Case Study – From Launch to Today
Brand Support Services Case Study – From Launch to Today 48 Label required administration by HCP Launch of Nursing Coordination program at Proherant High patient out of pocket Launch of co-pay assistance at PSKW Prescriber experience Direct to physician sampling dispensed from SCG third party logist
Slide 49: Case Study – Value and Growth
Case Study – Value and Growth 2008 2009 2010 2011 Product Sales/Market Share Growth 49 P ro d uc t Sal e s • Addition of Nurse Coordination • Staff expansion (alignment with field team) • Launch of physician web portal • Investment in business intelligence software • Launched physician buy and bill
Slide 50: Closing Remarks
Closing Remarks Nitin Sahney Chief Operating Officer 50
Slide 51: Specialty Care Group Operational Changes Since Reorganization
Specialty Care Group Operational Changes Since Reorganization 51 11/1/10 Group Formed EVP/President Hired 11/8/10 SVP – Operations SCG 11/1/2011–1/28/11 Evaluation of Existing SP Operations 1Q11 2Q11 3Q11 4Q11 2/5/11 VP Finance for ACS 2/17/11 Relocation of ACS 3/1/11 SVP/GM of ACS 4/19/11 Open New
Slide 52: Specialty Care Group Operational Milestones
Specialty Care Group Operational Milestones • Managed over $1B in commercial inventory annually • 99.97% inventory accuracy • Shipped over 19 million units in the past year • 99.97% shipment accuracy • Stored and managed over 1 million liters of plasma on a weekly basis • Market leader in plasma sup
Slide 53: Specialty Care Group Operational Milestones
Specialty Care Group Operational Milestones • Solved 3,000 reimbursement challenges weekly • Supported 350,000 active patients with specialty needs in the past year • Answered 4.8 million calls • Fulfilled 6 million prescriptions • Serviced 2 million hospice patients Supporting patients(1) 53 1. Res
Slide 54: Investment in Facilities
Investment in Facilities • Specialty Care Group – Third Party Logistics • Louisville, KY – Progress Distribution Center (132,000 sq. ft.) – National Turnpike Logistics Center (98,000 sq. ft.) » Opened in June 2011; expanding January 2013 • Erlanger, KY – Plasma Logistics Center (24,550 sq. ft.) » Op
Slide 55: Specialty Care Group Operational Milestones
Specialty Care Group Operational Milestones • Additional Pharma grade logistics center in Louisville (100,000 sq. ft.) • New Plasma logistics center in Erlanger, KY (25,000 sq. ft.) • Expansion of Brand Support service center footprint in Louisville, KY • Increase of over 100 new FTEs in Brand Suppo
Slide 56: Specialty Care Group Gaining Traction in the Marketplace
Specialty Care Group Gaining Traction in the Marketplace 0 5 10 15 20 25 30 4Q10 2Q12 # Contract Wins # RFPs Sales outreach increased nearly 300% Contract wins increased 500% 56
Slide 57: Specialty Care Group Financial Accomplishments Since Formation
Specialty Care Group Financial Accomplishments Since Formation $150 $200 $250 $300 $350 Revenue Quarterly Revenue (in millions) 3Q10 2Q12 57 $15 $20 $25 $30 $35 Adjusted Operating Profit Quarterly Adjusted Operating Profit(1) (in millions) 3Q10 2Q12 1. Excludes special items. A reconciliation of non
Slide 58: Specialty Care Group Maximizing Internal and External Opportunities
Specialty Care Group Maximizing Internal and External Opportunities Omnicare specialty care growth has been robust… and opportunities exist to further accelerate growth through: • Continued improvements to the organizational structure – Investments made to support solutions sales process – Platform-
Slide 59: Specialty Care Group Benefits
Specialty Care Group Benefits SCG Brings to Omnicare • Rapidly growing market • We believe our integrated offering has broad appeal with manufacturers • Diversifies Omnicare’s payer mix • SCG aligned with country’s efforts to improve healthcare efficiencies 59 Formation of Specialty Care Group has b
Slide 60: Omnicare Specialty Summit September 18, 2012
Omnicare Specialty Summit September 18, 2012